Testing two targeted cancer drugs for advanced solid tumors
Treatments studied
Part of Cancer clinical trials.
This early-stage study tests a combination of two study medicines (AK119 plus AK112) in people with advanced solid tumors that have grown or didn’t respond to standard treatment. It may help shrink tumors or improve how long people can stay on treatment by blocking cancer-related pathways.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old and can sign consent and follow study visits
- You have an advanced solid tumor that can’t be removed, and it has progressed or you couldn’t tolerate at least one standard treatment
- Your cancer has at least one measurable spot on scans that the study can track
- Your general health is good enough (ECOG 0 or 1) and you’re expected to live at least 3 months
- You have adequate blood counts and organ function for study treatment
- If you can become pregnant (or have a pregnant-capable partner), you agree to effective birth control during treatment and for 120 days after the last dose
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug, BA1203, for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if the drug is safe and whether it can help shrink tumors.
This trial tests a new drug called KH801, which may help the immune system fight cancer. It's for people whose cancer has spread or can't be removed and who have already tried other treatments without success. The goal is to see if the drug is safe and if it helps slow down the cancer.
This Phase 1/2 trial tests a combination of two immune-targeting drugs (AK109 and AK104) in people with advanced solid tumors that can’t be treated with standard options, or where standard treatment didn’t work or wasn’t tolerated. It aims to find safe dosing and whether the treatment can shrink tumors or control the disease.
This trial tests a new drug called AK138D1 for people with advanced solid tumors. It aims to see if the drug is safe and how well it works, especially for tumors that haven't been treated with HER3-targeted therapy before.
This study tests an experimental drug (AK146D1) for people with advanced solid tumors that are no longer responding to standard treatments. The goal is to see if it is safe and effective.
This trial tests a new drug called AK131 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and can help slow or shrink the cancer.
Hear when a new Solid Tumor, Adult trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.